MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Ms. Adelina Louie Ngar Yee made an individual purchase of 170,940 shares of the Company’s common stock as part of the Company’s recent private placement of common stock and warrants.
- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Ms. Adelina Louie Ngar Yee made an individual purchase of 170,940 shares of the Company’s common stock as part of the Company’s recent private placement of common stock and warrants.
- Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer, commented, “Our ongoing progress has encouraged our top investors to continue participating in our offerings.
- We appreciate the support of our top investor, Adelina, alongside Stan Smith’s participation in the same offering .
- Most recently she was the Chief Operating Officer of Internal Audit at HSBC Group.